Intellia (NTLA) Rockets 13% Ahead of Phase 3 Lonvo-Z Study Update

Intellia Therapeutics Inc. (NASDAQ:NTLA) is one of the 9 Stocks Crushing the Market With Surging Returns.

Intellia Therapeutics snapped a three-day losing streak on Thursday, soaring 13.29 percent to close at $14.75 apiece, as investors positioned portfolios ahead of the phase 3 results of its lonvo-z study in hereditary angioedema (HAE).

In a notice on its website, Intellia Therapeutics Inc. (NASDAQ:NTLA) said that it would present the late-breaking results at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul, Turkiye, on June 12-15.

For illustration purposes only. Photo by Gustavo Fring on Pexels

Lonvo-z is an experimental gene-editing therapy designed as a potential one-time functional cure for HAE, a rare, painful, and potentially fatal genetic condition that causes sudden, severe swelling in the face, limbs, and airways.

In April this year, Intellia Therapeutics Inc. (NASDAQ:NTLA) submitted a biologics license application with the Food and Drug Administration for the approval of lonvo-z following positive topline data, having met its primary and all key secondary endpoints.

“If approved, lonvo-z will become the world’s first in vivo CRISPR-based gene editing therapy,” Intellia Therapeutics Inc. (NASDAQ:NTLA) President and CEO John Leonard said.

“The promising results … reinforce our conviction that lonvo-z could revolutionize how HAE is treated for many patients, with the potential to free most of them from both attacks and the need for ongoing therapy with just one dose. We look forward to our continued engagement with the FDA as we seek to ease many of the burdens for people living with HAE,” he noted.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.